Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022
November 07 2022 - 8:00AM
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the
“Company”), a clinical-stage pharmaceutical company developing
innovative therapies for the treatment of advanced solid tumors and
other serious diseases, today announced that management will
participate in the following events:
|
• |
|
RNA at the Bench and Bedside III (November 8-10,
2022) |
|
|
|
Location:
Rosanne M. Crooke, PhD. Conference Center, Carlsbad, CA |
|
|
|
|
|
|
|
David Slack, President and
Chief Business Officer of Lisata, will participate
in one-on-one meetings during this event. For more information
about the RNA at the Bench and Bedside III, please visit
https://conferences.nature.com/event/7ad212a5-381e-43db-99e8-698ae7c7924b/summary. |
|
|
|
|
|
• |
|
Inv€$tival
Showcase 2022 (November 14, 2022) |
|
|
|
Location:
London, UK |
|
|
|
Presentation
format: In-person; corporate overview |
|
|
|
Presentation
Time: 2:30 p.m. (GMT) / 10:30 a.m. (ET) |
|
|
|
Company
Presenter: David J. Mazzo, PhD, Chief Executive Officer of
Lisata |
|
|
|
|
|
|
|
For more information about the
Inv€$tival Showcase, please visit
https://www.lsxleaders.com/investival-showcase. |
|
|
|
|
|
• |
|
Jefferies London
Healthcare Conference (November 15-17, 2022) |
|
|
|
Location:
London, UK |
|
|
|
|
|
|
|
Management will participate in
one-on-one meetings at the Jefferies conference. For more
information, please visit
https://www.jefferies.com/OurFirm/ConferenceList/Investment-Conferences/159. |
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company
dedicated to the discovery, development, and commercialization of
innovative therapies for the treatment of advanced solid tumors and
other major diseases. Lisata’s lead investigational product
candidate, LSTA1 (formerly known as CEND-1), is designed to modify
the tumor microenvironment by activating a novel uptake pathway
that allows anti-cancer drugs to penetrate solid tumors more
effectively. LSTA1 actuates an active transport system in a
tumor-specific manner, resulting in systemically co-administered
anti-cancer drugs more efficiently penetrating and accumulating in
the tumor, while normal tissues are not affected. LSTA1 has
demonstrated favorable safety, tolerability, and activity in
clinical trials to enhance delivery of standard-of-care
chemotherapy for pancreatic cancer. Lisata and its collaborators
have also amassed significant non-clinical data demonstrating
enhanced delivery of a range of emerging anti-cancer therapies,
including immunotherapies and RNA-based therapeutics. Lisata is
exploring the potential of LSTA1 to enable a variety of treatment
modalities to treat a range of solid tumors more effectively. In
addition, Lisata also has clinical development programs based on
its autologous CD34+ cell therapy technology platform. For more
information on the Company, please visit www.lisata.com.
Contact:
Investors and Media:Lisata Therapeutics, Inc.John MendittoVice
President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Apr 2023 to Apr 2024